A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Conditions: Low Grade Serous Ovarian Cancer Interventions: Drug: avutometinib + defactinib; Drug: Investigator Choice of Treatment (ICT) Sponsors: Verastem, Inc.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT) Not yet recruiting

https://clinicaltrials.gov/study/NCT06072781

Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials